investorscraft@gmail.com

Intrinsic value of Accuray Incorporated (ARAY)

Previous Close$2.17
Intrinsic Value
Upside potential
Previous Close
$2.17

VALUATION INPUT DATA (original, your and others' valuations)

ParameterOrig.Your
Date of valuation (DoV)  
Intrinsic value (IV) at DoV, $/sh  
IV at current val. algorithm, $/sh2.35 

The original valuation is based on fiscal year data as of 2021-06-30 and quarterly data as of 2022-03-31.

Registered users can save their valuation input data

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

NOTE: The bar chart shows historic and forecasted yearly revenue growth rates. Its purpose is to help you in determining what initial revenue rate you want to base your stock valuation on. Please make sure that you are confident in the value you select - for most stocks it is by far the most important parameter in valuation.

Company description

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. The company also offers the TomoTherapy System, including the Radixact System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. It markets its products in the United States directly, as well as through sales organizations, sales agents, and group purchasing organizations; and directly, as well as through distributors and sales agents in Europe, Asia, and South America to hospitals and stand-alone treatment facilities. The company was incorporated in 1990 and is headquartered in Sunnyvale, California.

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2021(a)2022202320242025202620272028202920302031203220332034203520362037203820392040204120422043204420452046

INCOME STATEMENT

Revenue growth rate, %3.5NaN
Revenue, $396NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m374NaN
Operating income, $m22NaN
EBITDA, $m29NaN
Interest expense (income), $mNaN
Earnings before tax, $m-5NaN
Tax expense, $m2NaN
Net income, $m-6NaN

BALANCE SHEET

Cash and short-term investments, $m117NaN
Total assets, $m480NaN
Adjusted assets (=assets-cash), $m363NaN
Average production assets, $m98NaN
Working capital, $m157NaN
Total debt, $m199NaN
Total liabilities, $m411NaN
Total equity, $m69NaN
Debt-to-equity ratio2.897NaN
Adjusted equity ratio-0.099NaN

CASH FLOW

Net income, $m-6NaN
Depreciation, amort., depletion, $m6NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m39NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-2NaN
Free cash flow, $m41NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m157
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount